SUBSCRIBE
SUBSCRIBE

Ipsen Biopharmaceuticals, Inc.

NEWS
Biotech Beach
The Day In Review: Tercica, Inc. And Ipsen Sign Cross-License Deal
July 19, 2006
 · 
1 min read
Business
Ipsen Joins Pfizer In Breast Cancer Trials
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
Policy
European Commission Approves Cabometyx® in Combination With Opdivo® as a First-Line Treatment for Patients Living With Advanced Renal Cell Carcinoma
March 31, 2021
 · 
13 min read
Drug Development
Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide)
February 22, 2021
 · 
15 min read
Deals
Ipsen Delivered Sales Growth and Margin Expansion in 2020 - Focused on Executing New Strategy and Delivering Financial Objectives in 2021
February 11, 2021
 · 
44 min read
Business
Ipsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs
January 20, 2021
 · 
7 min read
Drug Development
TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications
January 15, 2021
 · 
20 min read
Deals
Ipsen Highlights New Strategic Priorities and Provides Mid-Term Financial Outlook
December 1, 2020
 · 
9 min read
Genetown
Synthace and Ipsen Partner to Accelerate Novel Therapeutic Development Through Automation
November 5, 2020
 · 
4 min read
Deals
Ipsen Delivers Sales Growth in the First Nine Months of 2020 Despite the Impact of COVID-19 and Confirms Its 2020 Full Year Guidance
October 22, 2020
 · 
18 min read
Ipsen to Present 12 Abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress Taking Place Jointly With the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)1-13
October 8, 2020
 · 
13 min read
Business
Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer
September 25, 2020
 · 
7 min read
Load More